CClinicalTrials.gg
Enrolling by invitationNCT06103409Updated Oct 26, 2023

MSCs for the Treatment of Burn Wounds

A Phase 1/2 interventional study of Implantation of allogeneic MSCs on burn wounds in Burn Wound and Second- or Third-degree Burn, sponsored by Instituto Venezolano de Investigaciones Cientificas. Enrolling by invitation at 1 site in Venezuela. Open to participants aged 2 Weeks to 85 Years. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by Instituto Venezolano de Investigaciones Cientificas · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
2 Weeks to 85 Years
Sex
All
01

Study summary

The goal of this study is to evaluate the capacity of allogenic mesenchymal stromal cells form bone marrow (BM-MSC) or adipose tissue(Ad-MSC) to induce wound healing in patients with burn wounds.

Read the detailed description

Based on the paracrine and immunomodulatory effects of MSCs, they are considered promising cells for tissue engineering and skin regeneration in burn wounds. This protocol is designed to evaluate the efficacy of transplantation of allogenic BM-MSCs or Ad-MSCs, included in preclotted platelet-rich plasma (PRP), in patients with deep- or full-thickness burns (second- or third-degree / AB B or B degree). All patients will receive concomitant first-line treatments.

02

Conditions studied

  • Burn Wound
  • Second- or Third-degree Burn

Keywords

  • Burn wounds, skin regeneration, MSCs
03

Who can participate

Ages eligible
2 Weeks to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age between 2 weeks and 85 years old
  • Patient with second- or third-degree burn (AB/B or B).
  • Thermal burns
  • Electrical burns
  • Chemical burns
  • Informed consent of the patient or caretaker

Exclusion criteria

Exclusion Criteria:

  • First degree burn (A or AB)
  • Evidence of active infection at the wound site
  • Chronic malnutrition
  • Systemic inflammatory response syndrome (SIRS) or sepsis
  • Moderate or severe respiratory tract or lungs burn injuries
  • Autoimmune disease (e.g. multiple sclerosis, lupus erythematosus)
  • Severe pulmonary disease, hematologic disease, malignancy, or hypo-immunity.
  • Diabetes
  • Pregnancy
04

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Allogenic MSCs

    All Patients will receive conservative treatment before transplantation of allogenic MSCs embedded in autologous platelet rich plasma clot.

    Biological: Implantation of allogeneic MSCs on burn wounds

Interventions

  • BiologicalImplantation of allogeneic MSCs on burn wounds

    Transplantation of allogeneic MSCs in patients with deep- or full-thickness burns. Allogeneic MSCs embedded in autologous platelet rich plasma clot (PRP) are implanted onto the burned areas. The treated areas will be covered with conventional dressings and burned roll. Dressings will be changed after 5 days and then weekly. The total number of MSCs used in each patient varied according to the burn injury. In patients with larger burned areas, its necessary to apply new treatments with MSCs in affected areas, at intervals of at least 1 month. Implantation will be performed in the operating room. Patients will receive first line treatments.

    Also known as: Transplantation of MSCs on burn wounds

05

What researchers measure

Primary outcomes

  1. Re-epithelialization areas

    Re-epithelialization will be determined by clinical evaluations and recorded by digital color photographs

    Time frame: Up to 6 month

  2. Complete burn wound healing

    Time (days) to complete re-epithelialization of burned skin. It will be based on clinical evaluations and digital color photographs

    Time frame: Up to 12 month

06

Study locations

1 site
  • Instituto Venezolano de Investigaciones Cientificas
    Caracas, Miranda 1204, Venezuela
07

References and documents

Publications

  • Wittig O, Diaz-Solano D, Chacin T, Rodriguez Y, Ramos G, Acurero G, Leal F, Cardier JE. Healing of deep dermal burns by allogeneic mesenchymal stromal cell transplantation. Int J Dermatol. 2020 Aug;59(8):941-950. doi: 10.1111/ijd.14949. Epub 2020 Jun 5. PubMed 32501530 ↗
  • Pereira B, Duque K, Ramos-Gonzalez G, Diaz-Solano D, Wittig O, Zamora M, Gledhill T, Cardier JE. Wound healing by transplantation of mesenchymal stromal cells loaded on polyethylene terephthalate scaffold: Implications for skin injury treatment. Injury. 2023 Apr;54(4):1071-1081. doi: 10.1016/j.injury.2023.02.024. Epub 2023 Feb 13. PubMed 36801131 ↗
  • Ramos-Gonzalez G, Salazar L, Wittig O, Diaz-Solano D, Cardier JE. The effects of mesenchymal stromal cells and platelet-rich plasma treatments on cutaneous wound healing. Arch Dermatol Res. 2023 May;315(4):815-823. doi: 10.1007/s00403-022-02451-y. Epub 2022 Nov 3. PubMed 36326886 ↗
  • Ramos-Gonzalez G, Wittig O, Diaz-Solano D, Salazar L, Ayala-Grosso C, Cardier JE. Evaluation of epithelial progenitor cells and growth factors in a preclinical model of wound healing induced by mesenchymal stromal cells. Biosci Rep. 2020 Jul 31;40(7):BSR20200461. doi: 10.1042/BSR20200461. PubMed 32667622 ↗
08

Registry details

Key details

Study ID
NCT06103409
Lead sponsor
Instituto Venezolano de Investigaciones Cientificas
Collaborators
Unidad de Terapia Celular - IVIC, Hospital Pediátrico Niño Jesús, San Felipe, Yaracuy, Hospital Central Dr. Plácido D. Rodriguez Rivero, San Felipe, Yaracuy
Responsible party
Dylana Diaz Solano (Investigator, Instituto Venezolano de Investigaciones Cientificas) — Principal investigator
First posted
Oct 26, 2023
Start date
Jun 30, 2021
Primary completion
Jun 30, 2023
Completion
Jun 30, 2025 (estimated)
Last update
Oct 26, 2023

Study contacts

Olga L Wittig, MSc
principal investigator · Instituto Venezolano de Investigaciones Cientificas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion